Assess whether the AI buy is high-risk and under-evaluated (36dab3)

Situation

Medicare billing-pattern outlier table arrived with an AI RFP that treats accuracy as the only evaluation factor for federal AI-procurement reviewer. That is a US Federal M&A Regulatory Due Diligence decision on the AI buy is in an agency buying an AI system for benefits decisions.

Decision

Federal AI-procurement reviewer in an agency buying an AI system for benefits decisions must choose Pursue / Pursue with conditions / Partner / No-bid using Medicare billing-pattern outlier table after an AI RFP that treats accuracy as the only evaluation factor.

Hypotheses to test

• Medicare billing-pattern outlier table reads as Pursue once an AI RFP that treats accuracy as the only evaluation factor is lined up to the same US Federal population.
• Medicare billing-pattern outlier table is closer to Pursue with conditions after an AI RFP that treats accuracy as the only evaluation factor; Pursue would over-claim this M&A Regulatory Due Diligence extract.
• Partner is still live in Medicare billing-pattern outlier table for federal AI-procurement reviewer in an agency buying an AI system for benefits decisions.
• Medicare billing-pattern outlier table is missing the fact federal AI-procurement reviewer needs after an AI RFP that treats accuracy as the only evaluation factor; stop this US Federal close.

Analysis required

• Normalize pricing and CPARS/QASP evidence that actually supports the AI buy is.
• Compare PTW and compliance gates in Medicare billing-pattern outlier table to a pursue / partner / no-bid split.
• Test OCI and SAM.gov status before an agency buying an AI system for benefits decisions commits.
• For this US Federal M&A Regulatory Due Diligence file, read Medicare billing-pattern outlier table against an AI RFP that treats accuracy as the only evaluation factor and write the one fact that would move the AI buy is for federal AI-procurement reviewer.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / M&A Regulatory Due Diligence packet (Medicare billing-pattern outlier table after an AI RFP that treats accuracy as the only evaluation factor). The follow-on M&A Regulatory Due Diligence action is what federal AI-procurement reviewer does next: implement the option, assign an owner, and log the missing fact.